Nutriband (NASDAQ:NTRB) Upgraded at Wall Street Zen

Nutriband (NASDAQ:NTRB) was upgraded by analysts at Wall Street Zen to a “hold” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Nutriband in a research note on Monday, September 28th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Reduce”.

Nutriband Stock Down 0.8%

Shares of NTRB stock opened at $6.22 on Friday. The firm has a market cap of $75.64 million, a P/E ratio of -11.74 and a beta of 1.92. Nutriband has a 12-month low of $2.80 and a 12-month high of $9.19. The company has a 50 day moving average of $5.86 and a 200-day moving average of $4.28.

Nutriband (NASDAQ:NTRB) last posted its earnings results on Friday, September 4th. The company reported ($0.07) earnings per share for the quarter. Nutriband had a negative return on equity of 109.07% and a negative net margin of 430.35%. The business had revenue of $0.44 million during the quarter.

Nutriband Company Profile

Nutriband Inc (NASDAQ:NTRB) develops and manufactures transdermal patches and other wearable drug-delivery products for pharmaceutical, over-the-counter, consumer, and wellness markets. The company’s capabilities include product development, formulation, manufacturing, packaging, and private-label services for customers seeking patch-based delivery systems.

Nutriband’s portfolio includes consumer and wellness patches, as well as prescription-focused transdermal technologies. Its AVERSA platform is designed to incorporate abuse-deterrent features into transdermal products, with the goal of helping reduce the risk of drug extraction, misuse, or abuse.